首页> 外文期刊>Nanomedicine research journal. >Chemometric approach for developing nanostructured self-emulsifying drug delivery systems of rosuvastatin calcium containing a dietary lipid with improved biopharmaceutical performance
【24h】

Chemometric approach for developing nanostructured self-emulsifying drug delivery systems of rosuvastatin calcium containing a dietary lipid with improved biopharmaceutical performance

机译:含有膳食脂质含有膳食脂质的罗斯汀钙的纳米结构自乳化药物递送系统的化学计量方法

获取原文
       

摘要

Objective(s): The present work deals with the development of nanostructured self-emulsifying delivery system of rosuvastatin calcium containing a dietary lipid by chemometry principles for improving the biopharmaceutical performance of the drug. Excipient screening was performed on the basis of solubility of drug and phase behaviour study using aqueous titration method. A blend of liquid lipids, emulgents and coemulgents were used as for preparing the self-emulsifying delivery systems of the drug. Methods: Optimal mixture design was adopted for systematic optimization of the composition of self-emulsifying formulations and evaluated for emulsification time, globule size, polydispersity index, zeta potential and in vitro drug release. In vitro drug release in simulated fluids, and in vivo pharmacokinetic in rats was performed for comparing the biopharmaceutical performance. Results: The optimized self-nanoemulsifying formulation contained 15% of lipid (isopropyl myristate), 75% of emulgent (Tween 20) and 10% of cosolvent (ethanol), which exhibited fast emulsification in 150 second, globule size of 68 nm, zeta potential of 27 mV and more than 85% drug release within 30 minutes. Conclusions: Pharmacokinetic study in rats indicated 4.89 to 4.45-folds improvement in the values of AUC and Cmax, and 0.95-folds reduction in Tmax from the self-nanoemulsifying system vis-à-vis the pure drug. Overall, the developed nanolipidic formulation of rosuvastatin indicated superior efficacy in augmenting the drug dissolution and absorption performance.
机译:目的:目前的工作涉及通过化学测量原理含有膳食脂质的罗斯汀钙的纳米结构自乳化递送系统的开发,从而提高药物的生物制药性能。基于药物和相行为研究的溶解性使用滴定法的溶解度进行赋形剂筛选。使用液体脂质,仿效剂和加入的混合物,用于制备药物的自乳化递送系统。方法:采用最佳混合设计,用于系统优化自乳化制剂的组成,评价乳化时间,球状大小,多分散性指数,Zeta电位和体外药物释放。在模拟流体中体外药物释放,并进行大鼠体内药代动力学进行比较生物制药性能。结果:优化的自纳乳乳化制剂含有15%的脂质(异丙基肌酐),75%的仿效(吐温20)和10%的共溶剂(乙醇),其在150秒内表现出快速乳化,球状大小为68nm,Zeta在30分钟内潜力27 mV,超过> 85%的药物释放。结论:大鼠的药代动力学研究表明AUC和CMAX值的改善4.89至4.45倍,以及从自纳中乳化体系Vis-in-Vis的TMAX减少0.95倍。总的来说,罗斯汀的开发的纳米脂化制剂表明增强药物溶解和吸收性能的优异功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号